Form 4: Intellia Therapeutics Director Fred Cohen Granted Significant Equity Awards

Intellia Therapeutics, Inc. Director Fred E. Cohen was granted 8,000 restricted stock units and options to purchase 11,450 shares of common stock on June 11, 2025.

Summary

• Fred E. Cohen, a Director of Intellia Therapeutics, Inc. (NTLA), acquired 8,000 shares of common stock through a grant of restricted stock units (RSUs) on June 11, 2025.
• These RSUs represent a contingent right to receive one share of Intellia common stock for each unit, with a transaction price of $0.00.
• Following this transaction, Mr. Cohen directly beneficially owns 57,453 shares of common stock.
• Additionally, Mr. Cohen was granted stock options to purchase 11,450 shares of common stock on June 11, 2025, with an exercise price of $8.37 per share.
• These stock options vest in full on the earlier of the first anniversary of the grant date (June 11, 2026) or the date of the next annual meeting of stockholders following the grant date.
• The stock options have an expiration date of June 10, 2035.
• The filing also includes a Limited Power of Attorney, dated October 31, 2024, appointing James Basta and Edward Dulac to execute SEC filings on behalf of Fred E. Cohen.

Sentiment

Score: 7

Explanation: The grant of equity awards to a director is generally a positive signal, indicating alignment of interests and incentivizing long-term performance. However, it is a grant, not an open market purchase, which typically carries less strong sentiment than a direct cash investment by an insider.

Positives

• Director Fred E. Cohen was granted 8,000 restricted stock units, aligning his interests with shareholders.
• Mr. Cohen also received options to purchase 11,450 shares, indicating continued commitment to the company's long-term performance.
• Equity grants to directors are a common way to incentivize long-term value creation.

Future Outlook

The vesting schedule for the stock options indicates a future commitment period for the director, aligning his incentives with the company's long-term performance.

Industry Context

This transaction is a standard form of executive and director compensation in the biotechnology industry, where equity grants are used to incentivize long-term commitment and align interests with shareholders, particularly in companies like Intellia Therapeutics which are focused on long-term drug development and clinical milestones.

Corporate Governance

Stakeholder Impact

• Shareholders: The equity grants align the director's interests with shareholders, potentially leading to decisions that enhance long-term shareholder value.
• Employees: No direct impact on employees mentioned.
• Customers: No direct impact on customers mentioned.
• Suppliers: No direct impact on suppliers mentioned.
• Creditors: No direct impact on creditors mentioned.

Next Steps

• The stock options granted on June 11, 2025, will vest in full on the earlier of June 11, 2026, or the date of the next annual meeting of stockholders following the grant date.

Key Dates

Recommendation

Keywords

Intellia Therapeutics, NTLA, Fred E. Cohen, SEC Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Equity Grant, Director Compensation, Biotechnology, Gene Editing